AzTrials
AzTrials

Mitral Valve ProlapseNCT03609931

Patient Specific Mitral Valve Modeling for Surgical Planning and Training

An observational study of Mitral Valve Prolapse and Mitral Regurgitation, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Mitral valve disease is a common pathologic problem occurring in approximately 2% of the general population but climbing to 10% in those over the age of 75 in Canada[1]. This project has three primary goals all of which will positively affect cardiac patient care. Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
Mitral Valve Model
Type of treatment
Surgery or procedure
How many people
65 participants
Where
No sites listed yet
Study dates
Jul 2018to Jan 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Adult, Older adult

Study population: Adult patients with mitral regurgitation scheduled to undergo mitral valve repair with either a open heart surgical technique or with a MitraClip

Who may be able to join

  • Patients undergo mitral valve repair with either surgery of MitraClip techniques
  • Over 18 years old

Who cannot join

  • Unable to place TEE probe
  • Refuse consent

Trial locations and contacts

No sites are listed yet.

Daniel Bainbridge, MD FRCPC contact

5192004235

daniel.bainbridge@lhsc.on.ca

About this study

Mitral valve disease is a common pathologic problem occurring in approximately 2% of the general population but climbing to 10% in those over the age of 75 in Canada[1]. This project has three primary goals all of which will positively affect cardiac patient care.

  1. Create patient specific MV models for complex repairs that will allow surgeons the opportunity to practice the repair. 2) Potentially predict the outcomes following minimally invasive repair techniques such as transcatheter treatments (e.g., MitraClip). 3) Provide a model to train individuals on mitral valve repair techniques.
Read the detailed description

BACKGROUND Mitral valve disease is a common pathologic problem occurring in approximately 2% of the general population, but climbing to 10% in those over the age of 75 in Canada. Of this group, approximately 20% have a sufficiently severe form of the disease that may require surgical intervention to restore normal valve function and prevent early mortality [4]. Evidence indicates that the surgeon's individual volume of mitral valve repair cases performed is a determinant of not only successful mitral repair rates, but also freedom from reoperation, and patient survival. For patients previously deemed inoperable due to co-morbidities, new techniques to treat mitral valve disease are being developed. However, assessing the optimal approach and the point at which clinical benefit is exceeded by the poor value or futility of the procedure is one of the biggest clinical challenges for physicians.

In the past decade, 3D echocardiography has emerged as a standard of care in diagnostic and interventional imaging for cardiac surgery and cardiology. This, coupled with the emergence of inexpensive 3D printing technology has led researchers and clinicians to explore how improved imaging and additive manufacturing can be used to improve patient outcomes.

In this context, the investigators have completed a proof-of-concept workflow for creating dynamic, patient specific mitral valve models. In concert with a left ventricle simulator 8], these valve models can mimic patient valve pathologies both anatomically and dynamically, as shown in Doppler ultrasound. In a 10 patient retrospective study, the investigators have demonstrated the ability to accurately re-create patient pathology, perform realistic surgical repairs, and assess realistic valve function post repair. The study team's vision is to create a simulator that can be used to assess patient candidacy for percutaneous interventions, assess different repair options for both percutaneous and surgical interventions, and finally use the model as a simulator for competency-based MV interventions.

RATIONALE Based on our successful proof of concept, the goal is to translate this technology to clinical use by validating our valve models. There are two primary long term goals. First, to validate a system for using patient specific MV models to: 1- assess intervention options, and 2: plan repair strategies for improved patient outcomes. Second, by building a database of MV pathologies, create a competency based simulator/trainer to provide surgeons with increased experience in MV repair techniques.

OBJECTIVES

  1. Validate the accuracy of patient specific MV pathologies and repairs in a prospective 65 patient study;
  2. Optimize our work-flow for creating valve models, in terms of accuracy, manufacture time required, and expense;
  3. Validate the accuracy of our patient models for both surgical cases and transcatheter MitraClip interventions;
Being tested
Mitral Valve Model
Keywords
Mitral Valve
Medical subject headings
Mitral Valve Prolapse, Mitral Valve Insufficiency

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Mitral Valve ModelProcedure or surgery

    Creation of a mitral valve patient specific model to see if it mimics the patients valve

Study groups in NCT03609931
Study groupRoleWhat they receive
Mitral Valve repairPatients undergoing mitral valve repair
Receives: Procedure: Mitral Valve Model

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. MR following patient/model repair

    The degree and location of residual MR following mitral repair surgery

    Measured: Creation and assessment of the model within 1 week before or after surgery/intervention on the patient.

Secondary outcomes (19)
  1. 2D measurements of the mitral valve: Anterolateral-Posteromedial Diameter

    A 2D measurements taken from the echocardiography images of the mitral valve and model

    Measured: Assessment of model within 1 week of surgical or interventional repair on the patient

  2. 2D measurements of the mitral valve:Annular Height

    A 2D measurements taken from the echocardiography images of the mitral valve and model

    Measured: Assessment of model within 1 week of surgical or interventional repair on the patient

  3. 2D measurements of the mitral valve: Annular 3D Circumference

    A 2D measurements taken from the echocardiography images of the mitral valve and model

    Measured: Assessment of model within 1 week of surgical or interventional repair on the patient

  4. 2D measurements of the mitral valve:Annular 2D Area

    A 2D measurements taken from the echocardiography images of the mitral valve and model

    Measured: Assessment of model within 1 week of surgical or interventional repair on the patient

  5. 2D measurements of the mitral valve: Annular Ellipticity

    A 2D measurements taken from the echocardiography images of the mitral valve and model

    Measured: Assessment of model within 1 week of surgical or interventional repair on the patient

  6. 2D measurements of the mitral valve: Anterior Leaflet 3D Area

    A 2D measurements taken from the echocardiography images of the mitral valve and model

    Measured: Assessment of model within 1 week of surgical or interventional repair on the patient

  7. 2D measurements of the mitral valve: Posterior Leaflet 3D Area

    A 2D measurements taken from the echocardiography images of the mitral valve and model

    Measured: Assessment of model within 1 week of surgical or interventional repair on the patient

  8. 2D measurements of the mitral valve: Leaflet 3D Area

    A 2D measurements taken from the echocardiography images of the mitral valve and model

    Measured: Assessment of model within 1 week of surgical or interventional repair on the patient

  9. 2D measurements of the mitral valve: Mitral Regurgitation Orifice Area

    A 2D measurements taken from the echocardiography images of the mitral valve and model

    Measured: Assessment of model within 1 week of surgical or interventional repair on the patient

  10. 2D measurements of the mitral valve: Tenting Volume

    A 2D measurements taken from the echocardiography images of the mitral valve and model

    Measured: Assessment of model within 1 week of surgical or interventional repair on the patient

  11. 2D measurements of the mitral valve: Nonplanar Angle

    A 2D measurements taken from the echocardiography images of the mitral valve and model

    Measured: Assessment of model within 1 week of surgical or interventional repair on the patient

  12. 2D measurements of the mitral valve: tenting Height.

    A 2D measurements taken from the echocardiography images of the mitral valve and model

    Measured: Assessment of model within 1 week of surgical or interventional repair on the patient

  13. ICU LOS

    length of stay in the ICU

    Measured: Postoperative period until ICU discharge (expected mean of 1 days)]

  14. Hospital LOS

    Length of stay in hospital

    Measured: Postoperative period until hospital discharge (expected mean of 5 days)

  15. Delirium

    Delirium in hospital

    Measured: Postoperative period until hospital discharge (expected mean of 5 days)

  16. Renal failure requiring dialysis

    Dialysis

    Measured: Postoperative period until hospital discharge (expected mean of 5 days)

  17. Stroke,TIA

    Diagnosis of stroke

    Measured: Postoperative period until hospital discharge (expected mean of 5 days)

  18. Death in Hospital

    Death

    Measured: Postoperative period until hospital discharge (expected mean of 5 days)

  19. Reoperation for Bleeding

    Return to the operating room for re-exploration of the surgical procedure due to excess blood loss in the ICU

    Measured: Postoperative period until hospital discharge (expected mean of 5 days)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Aug 2018
  2. Study startJul 2018 (estimated)
  3. Primary completionAug 2019 (estimated)
  4. Study completionJan 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
65 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03609931
Sponsor's protocol ID
111462
Status last verified
Jul 2018
First submitted
12 Jun 2018
Last updated
1 Aug 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Ginty O, Moore J, Peters T, Bainbridge D. Modeling Patient-Specific Deformable Mitral Valves. J Cardiothorac Vasc Anesth. 2018 Jun;32(3):1368-1373. doi: 10.1053/j.jvca.2017.09.005. Epub 2017 Sep 7.

    PubMed 29221976

Questions about this trial

What is this clinical trial studying?

An observational study of Mitral Valve Prolapse and Mitral Regurgitation, run by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Daniel Bainbridge, MD FRCPC (5192004235, daniel.bainbridge@lhsc.on.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

MR following patient/model repair (time frame: Creation and assessment of the model within 1 week before or after surgery/intervention on the patient.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03609931, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Aug 2018.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in